This article is for educational purposes only. Always consult your healthcare provider before starting, stopping, or changing GLP-1 medication.

For the first time, semaglutide — the active ingredient in Wegovy and Ozempic — is available in the US as a once-daily tablet for weight loss, not just a weekly injection. Novo Nordisk launched the oral Wegovy pill in early January 2026, and by summer it had become, in the company's own words, one of the strongest pharmaceutical launches by prescription volume on record, crossing more than three million prescriptions within roughly five months (Zacks Investment Research, July 11, 2026). On top of that, Novo Nordisk just dropped self-pay pricing to as low as $149 a month for starter doses (pharmaphorum, July 10, 2026), and the pill just secured its first European approval in the UK this month (Zacks Investment Research, July 11, 2026).

If you've been waiting for a pill-based alternative to weekly injections, or you're simply trying to understand what's different about this version of Wegovy, here's a complete breakdown of the launch, the dosing schedule, real pricing, and how it stacks up against both injectable Wegovy and Eli Lilly's competing pill, Foundayo.

What Exactly Launched, and When

Novo Nordisk received FDA approval for the oral Wegovy pill (semaglutide 25 mg tablet) in December 2025 and launched it commercially in the US in early January 2026 (Novo Nordisk press release via Globenewswire). It's the same active ingredient found in injectable Wegovy and Ozempic, reformulated with an absorption-enhancing technology so a meaningful dose of semaglutide can survive the digestive tract and reach the bloodstream — something that wasn't possible with older oral semaglutide formulations at weight-loss-relevant doses.

Why This Launch Is a Bigger Deal Than It Sounds

Weekly injections have been the single biggest barrier keeping some patients away from GLP-1 therapy altogether. An oral option removes needles from the equation entirely, and the uptake numbers reflect that: more than 80% of oral Wegovy prescriptions have gone to patients who had never previously used a GLP-1 medicine, according to Novo Nordisk data cited by industry analysts (Zacks Investment Research). That's a meaningfully different growth pattern than earlier GLP-1 launches, which mostly recruited from a pool of patients already comfortable with injectables.

The Dosing Schedule, Step by Step

Month 1: 1.5 mg

Nearly everyone starts here, regardless of how much weight they ultimately want to lose. This low starting dose is designed to reduce nausea and other GI side effects during the adjustment period.

Month 2: 4 mg

The second escalation step. Side effects at this stage are typically similar to or slightly milder than what patients experience during injectable Wegovy's early escalation phase.

Month 3: 9 mg

A transitional dose on the way to the maintenance level.

Month 4 Onward: 25 mg (Maintenance)

This is the dose used in the pivotal OASIS trials and the one associated with the ~16.6% average weight reduction result. Most patients remain on 25 mg long-term unless their prescriber adjusts the plan for tolerability or other clinical reasons.

The Non-Negotiable Rule: How You Have to Take It

Unlike Eli Lilly's competing oral GLP-1, Foundayo (orforglipron), the oral Wegovy pill has a strict administration routine:

  • Take it first thing in the morning, before any food, drink, or other oral medications.
  • Swallow it with no more than 4 ounces (about 120 mL) of plain water.
  • Wait at least 30 minutes before eating, drinking anything else, or taking other medications.

This routine exists because semaglutide's oral absorption is highly sensitive to stomach contents — food or excess liquid can block the tablet's special coating from working properly, sharply reducing how much drug actually reaches your bloodstream. If mornings are unpredictable for you, this is the single biggest practical difference to weigh against Foundayo, which has no such food or water restriction. See our Foundayo complete guide for a full breakdown of that alternative.

Pricing: What It Actually Costs in 2026

Self-Pay (Cash) Pricing

  • 1.5 mg and 4 mg (starter doses): $149/month
  • 9 mg and 25 mg (higher/maintenance doses): $299/month
  • The temporary discounted rate on the 4 mg dose was set to rise to $199/month after April 15, 2026 (pharmaphorum)

How That Compares

Injectable Wegovy's list price without insurance has historically hovered around $1,300–$1,400/month. Even at the higher $299/month maintenance-dose tier, the oral pill's self-pay price represents a substantial discount off injectable list price — though insurance coverage, when available, can change the math significantly in either direction depending on your plan's formulary and prior authorization requirements.

Insurance Coverage Notes

Plans that already cover injectable Wegovy do not automatically cover the oral formulation. If you're currently covered for injectable Wegovy and want to switch to the pill, check with your insurer about formulary status and whether a new prior authorization is required.

How Effective Is It, Really?

The OASIS 4 clinical trial found that patients taking the 25 mg daily dose lost an average of 16.6% of body weight, compared to 2.7% for those on placebo, over roughly 64 weeks (pharmaphorum). Novo Nordisk has stated this efficacy "rivals" the once-weekly injectable version of the drug — and the numbers back that up: injectable Wegovy's STEP trials showed roughly 15–17% average weight reduction, putting the two formulations in a very similar efficacy range.

How It Compares to Foundayo (Orforglipron)

Foundayo, Eli Lilly's competing oral GLP-1, showed roughly 11–12% average weight reduction at its highest studied dose in trials — modestly below the oral Wegovy pill's ~16.6% figure, though the two drugs have not been directly compared head-to-head in a published randomized trial as of mid-2026. Foundayo's main practical advantage is flexibility: no food, water, or timing restrictions.

Real-World Momentum So Far in 2026

The launch numbers have surprised even industry analysts. Novo Nordisk has publicly described it as one of the strongest US pharmaceutical launches by volume on record (Zacks Investment Research). By comparison, Foundayo's early prescription volume trailed meaningfully behind the oral Wegovy pill's pace during their respective first several weeks on the market.

Beyond the US, the oral Wegovy pill received a CHMP recommendation for EU approval in May 2026 and became the first daily GLP-1 weight-loss pill approved in the UK this month, marking Novo Nordisk's first international expansion of the oral formulation outside its original US market (Zacks Investment Research).

Should You Switch From Injectable Wegovy to the Pill?

This is a personal decision to make with your prescriber, but a few practical factors matter most:

  • If mornings are chaotic or unpredictable for you (shift work, young kids, inconsistent schedules), the strict empty-stomach/30-minute-wait rule may be harder to sustain daily than a once-weekly injection.
  • If needles are the main barrier keeping you from starting or continuing GLP-1 therapy, the pill removes that obstacle entirely.
  • If cost is the deciding factor, run the numbers for your specific insurance situation — self-pay pricing on the pill can undercut injectable list price substantially, but coverage rules vary by plan.

For a full breakdown of pricing pathways across all major GLP-1 options, see our complete GLP-1 cost guide.

Where to Start If You Don't Have a Prescription Yet

If you're interested in starting a GLP-1 medication — oral or injectable — and don't currently have a prescriber, SkinnyRx via GLPTree connects patients with licensed telehealth providers who can evaluate eligibility for oral and injectable GLP-1 options, including financing plans for patients without full coverage.

Educational content only. Not medical advice. Talk to a licensed healthcare provider before starting or switching any GLP-1 medication.

Frequently Asked Questions

When did the oral Wegovy pill launch in the US?

Novo Nordisk received FDA approval in December 2025 and launched the oral Wegovy pill commercially in the US in early January 2026 ([Novo Nordisk press release](https://via.ritzau.dk/pressemeddelelse/14736766/novo-nordisk-as?publisherId=90446&lang=en)).

How much does the oral Wegovy pill cost per month?

Self-pay pricing starts at $149/month for the 1.5 mg and 4 mg starter doses, rising to $299/month for the 9 mg and 25 mg maintenance doses ([pharmaphorum](https://pharmaphorum.com/news/novo-nordisk-launches-wegovy-pill-149-month)).

How do you take the oral Wegovy pill?

Take it first thing in the morning on an empty stomach with no more than 4 ounces of plain water, then wait at least 30 minutes before eating, drinking, or taking other medications.

Is the oral Wegovy pill as effective as the injection?

Clinical trial data suggests comparable efficacy — the OASIS 4 trial found a 16.6% average weight reduction on the 25 mg oral dose, in the same general range as injectable Wegovy's 15–17% results in the STEP trials.

What's the difference between oral Wegovy and Foundayo?

Both are oral GLP-1 weight-loss pills, but oral Wegovy requires strict empty-stomach, morning-only dosing with a 30-minute wait before food or drink, while Foundayo (orforglipron) can be taken any time of day, with or without food or water restrictions. Trial data suggests oral Wegovy may produce somewhat greater average weight loss.

Does insurance cover the oral Wegovy pill?

It depends on your specific plan. Coverage for injectable Wegovy does not automatically extend to the oral formulation — check your formulary and ask about prior authorization requirements.

Is the oral Wegovy pill available outside the US?

Yes — it received a CHMP recommendation for EU approval in May 2026 and gained approval in the UK in July 2026, making the UK the first European country to approve a daily GLP-1 weight-loss pill.

Sources

  1. pharmaphorum — Novo Nordisk launches Wegovy pill at $149 a month:pharmaphorum.com (July 10, 2026)
  2. Novo Nordisk / Globenewswire — Novo Nordisk A/S press release on Wegovy pill US launch:via.ritzau.dk (December 22, 2025)
  3. Zacks Investment Research — Novo Nordisk Gains 7% in a Week: How Should Investors Play the Stock:zacks.com (July 11, 2026)
  4. pharmaphorum — Wegovy pill shows strong early uptake, as rival looms:pharmaphorum.com (July 10, 2026)